Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
Did Hedge Funds Make The Right Call On argenx SE (ARGX) ?
04:15pm, Monday, 20'th Jul 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
argenx (ARGX): Strong Industry, Solid Earnings Estimate Revisions
01:24pm, Wednesday, 01'st Jul 2020
argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is argenx SE (ARGX) A Good Stock To Buy?
03:09pm, Monday, 15'th Jun 2020
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investmen
argenx announces closing of global offering
08:00pm, Monday, 01'st Jun 2020
Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea
argenx announces full exercise of underwriters’ option to purchase additional ADSs
05:00am, Friday, 29'th May 2020
Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea
argenx raises $750 million in gross proceeds in a global offering
04:15am, Thursday, 28'th May 2020
Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea
argenx Up on Positive Data from Pivotal Efgartigimod Study
02:08pm, Wednesday, 27'th May 2020
argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.
The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas
11:25am, Wednesday, 27'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * A
argenx announces launch of proposed global offering
08:01pm, Tuesday, 26'th May 2020
Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea
Here's Why argenx Stock Is Soaring Today
04:57pm, Tuesday, 26'th May 2020
Shares of argenx (NASDAQ: ARGX), a clinical-stage biotechnology company, are on the move following positive results from the Adapt trial of efgartigimod. An impressive 67.7% of those treated with ef
argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis
05:00am, Tuesday, 26'th May 2020
Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cance
argenx SE (ARGX) Q1 2020 Earnings Call Transcript
07:30pm, Thursday, 14'th May 2020
A press release with our first quarter 2020 business update and financial results was issued earlier today and can be found on our website along with the presentation for today's webcast. Thank you,
argenx reports first quarter 2020 financial results and provides business update
05:00am, Thursday, 14'th May 2020
- Topline data readout from Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis on track for mid-2020 and Biologics License Application filing.
Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates
01:52pm, Tuesday, 12'th May 2020
Halozyme (HALO) reports wider-than-expected Q1 loss. Shares down.
The argenx (EBR:ARGX) Share Price Gained 1374% And Shareholders Are Jubilant
09:22am, Monday, 11'th May 2020
We think all investors should try to buy and hold high quality multi-year winners. While not every stock performs...
